Development of herpes simplex virus disease in patients who are receiving cidofovir

Clinical Infectious Diseases

Volumn 41, Issue 5, 2005, Pages 676-680

  Wyles, David L ^a,e   Patel, Amita ^f   Madinger, Nancy ^b,c   Bessesen, Mary ^d   Krause, Philip R ^f   Weinberg, Adriana ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e Division of Infectious Diseases   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; CORTICOSTEROID; DNA POLYMERASE; FLUCONAZOLE; FOSCARNET; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; MELPHALAN; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PROBENECID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIGEN REDUCTION ASSAY; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA SEQUENCE; DRUG SENSITIVITY; DYSPHAGIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IC 50; IN VIVO STUDY; LUNG INFILTRATE; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; TONGUE DISEASE; VIRUS INFECTION; VIRUS ISOLATION;

ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CYTOSINE; DRUG RESISTANCE, VIRAL; FEMALE; HERPES SIMPLEX; HUMANS; MALE; PHOSPHONIC ACIDS; SIMPLEXVIRUS;

EID: 23844513759     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432477     Document Type: Article

References (15)

1. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex virus infections. N Engl J Med 1981; 305:63-7.
2. Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: An emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000; 31:927-35.
3. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis 2000; 181:2055-8.
4. Reyes M, Shaik N, Graber J, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and HIV clinics. Arch Intern Med 2003; 163:76-80.
5. Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect 1996; 33:235-48.
6. Sacks S, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex. Ann Intern Med 1989; 111:893-9.
7. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325:551-5.
8. DeClercq E, Holy A. Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl) cytosine in various models of herpes simplex virus infection in mice. Antimicrob Agents Chemother 1991; 35:701-6.
9. Martinez CM, Luks-Golger DB. Cidofovir use in acyclovir-resistant herpes infection. Ann Pharmacother 1997; 31:1519-21.
10. Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994; 170:570-2.
11. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994; 18:570-8.
12. Weinberg A, Bate BJ, Masters HB, et al. Activity of penciclovir and acyclovir in vitro against Herpes simplex types 1 and 2. Antimicrob Agents Chemother 1992; 36:2037.
13. Mendel DB, Tai CY, Barkhimer DB, Kern ER, Chen MS. Characterization of an in-vitro selected herpes simplex virus type 2 strain with decreased susceptibility to cidofovir [abstract 118]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: Foundation for Retrovirology and Human Health, 1997. Available at: http:// www.retroconference.org/retrovirus97/abstracts/a118_abstract.htm.
14. Andrei G, Snoeck R, De Clerq E, Esnouf R, Fiten P, Opdenakker G. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J Gen Virol 2000; 81:639-18.
15. Bestman-Smith J, Bovin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virology 2003; 77:7820-9.